FILGRASTIM
Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma
Eric Jacobsen, MDprotein_peptidePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
12 Active assets in the Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cyclophosphamide National Cancer Institute (NCI) | Phase 2 | BB |
Inno-206 Eric Jacobsen, MD | Phase 2 | B |
Azacitidine National Cancer Institute (NCI) | Phase 2 | B |
PREDNISONE TABLETS Eric Jacobsen, MD | Phase 2 | CCC |
Cytosin-Arabinosid Eric Jacobsen, MD | Phase 2 | CCC |
View all 12 →
Same molecule, other indications
FILGRASTIM is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →